Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

15 results about "Sindbis virus" patented technology

Sindbis virus (SINV) is a member of the Togaviridae family, in the alphavirus subfamily. The virus was first isolated in 1952 in Cairo, Egypt. The virus is transmitted by mosquitoes (Culex spp.) SINV causes sindbis fever in humans and the symptoms include arthralgia, rash and malaise. Sindbis fever is most common in South and East Africa, Egypt, Israel, Philippines and parts of Australia. Sindbis virus is an "arbovirus" (arthropod-borne) and is maintained in nature by transmission between vertebrate (bird) hosts and invertebrate (mosquito) vectors. Humans are infected with Sindbis virus when bitten by an infected mosquito. SINV has been linked to Pogosta disease in Finland, Ockelbo disease in Sweden and Karelian fever in Russia.

Substituted tetrahydrobenzothiophene and tetrahydropyridothiophene derivatives as potential antiviral agents

PCT designated stageWO2025175175A1Organic chemistryAntiviralsBovine Viral Diarrhea VirusesTick-borne encephalitis virus TBEV
The present disclosure is concerned with substituted tetrahydrobenzothiophene and tetrahydropyridothiophene compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds in the treatment of viral infections due to a Flavi virus (e.g, yellow fever, Japanese encephalitis, dengue (DENV), West Nile virus (WNV), zika (ZIKV), tick-bome encephalitis virus. Kunjin virus. Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Hepatitis C virus) or an Alphavirus (e.g., Venezeulan equine encephalitis virus, chikungunya virus (CHIKV), Ross River virus, Mayaro virus, Sindbis virus). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:MOUKHA CHAFIQ OMAR +7

In cellulo syntheses of targeting-ligand-conjugatable, RNA-specific, enveloped virus-like particles

PCT designated stageWO2026142973A2IntracellularBinding site
Embodiments of the invention disclosed herein involve the selective engineering of Sindbis virus so as to generate cells that make enveloped virus-like particles that contain therapeutic mRNAs, and whose membrane proteins have been mutated to serve as modular binding sites for cell-targeting ligands.
Owner:RGT UNIV OF CALIFORNIA

Application of insect protein Pea and homologous protein thereof in resistance to insect-borne virus infection

PendingCN119020317AReduced ability to carry Sindbis virusinfection controlPeptide/protein ingredientsHydrolasesBiotechnologyDrosophila ornatifrons
The invention discloses an application of insect protein Pea and homologous protein thereof in resistance to arthrovirus infection, and belongs to the technical field of biology. The insect protein Pea is fruit fly Pea protein, and homologous protein of the insect protein Pea comprises aedes albopictus, aedes aegypti and human homologous protein. According to the application, the effect of the fruit fly Pea protein and the homologous protein of the fruit fly Pea protein in resisting the Sindbis virus is found, the Pea protein plays a role in inhibiting the Sindbis virus in fruit flies and mosquitoes, and a human homolog DHX8 of the Pea protein plays an antiviral role in U2OS cells. Based on the effects of the drosophila melanogaster Pea protein and the homologous protein thereof, the drosophila melanogaster Pea protein can be used for developing anti-Sindbis virus drugs, and overexpression of the Pea protein or the homologous protein thereof can weaken the capability of vector insects for carrying Sindbis viruses, so that the infection and propagation of the Sindbis viruses in nature are controlled.
Owner:WUHAN UNIV

Kit for detecting CHIKV, DENV, SINV and JEV through one-step method

The invention relates to a kit capable of simultaneously detecting chikungunya virus (CHIKV), dengue virus (DENV), Sindbis virus (SINV) and Japanese encephalitis virus (JEV). The kit comprises a primer pair I for detecting CHIKV, a primer pair II for detecting DENV, a primer pair III for detecting SINV and a primer pair IV for detecting JEV. The kit disclosed by the invention can be used for simultaneously carrying out one-step fluorescent quantitative PCR detection on CHIKV, DENV, SINV and JEV, the sensitivity and the specificity of the kit are high, and stable and effective fluorescent signals can be obtained when the copy number of fragments in a detection sample reaches 250 copies / mL.
Owner:WUHAN UNIV OF SCI & TECH

A multiplex qPCR primer probe set, kit, detection method and application for detecting alphaviruses

PendingCN122382262AMultiplexAssociated organism
The application discloses a multiplex qPCR primer probe set, a kit, a detection method and application for detecting alphaviruses, and belongs to the technical field of molecular biological detection. The application designs a set of primer probe combination for a plurality of alphaviruses capable of infecting insect cell lines, including western equine encephalitis virus, eastern equine encephalitis virus, sindbis virus, chikungunya virus, AURA virus and Venezuelan equine encephalitis virus. The combination realizes synchronous detection and identification of a plurality of target viruses in one reaction system. The application also provides a kit containing the primer probe set and a corresponding detection method. The detection method has the advantages of wide coverage, high detection sensitivity, strong specificity, good anti-matrix interference capability and the like, and is suitable for safety detection and quality control of alphavirus contamination in insect cell banks, cell cultures and related biological products.
Owner:SINO BIOLOGICAL INC

A non-neurotoxic vsv vector recombinant oncolytic virus carrying sindbis virus g protein

The application discloses a non-neurotoxic VSV vector recombinant oncolytic virus carrying a Sindbis virus G protein, and is a self-replicating recombinant oncolytic virus VSV-SING which is obtained by replacing the G protein coding gene of a wild type VSV with the G protein coding gene of a Sindbis virus through reverse genetic manipulation technology, and has non-neurotoxicity and high oncolytic activity.
Owner:ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD

Modulation of GAS7 expression and / or activity for the modulation of viral replication.

Macrophages (Mφ) are crucial for pathogen detection and elimination, and also serve as a microenvironment for replication of multiple infectious pathogens. This delicate balance between viral replication and antiviral response remains largely unknown at the molecular level. Addressing this issue is physiologically important given the persistent threat posed by emerging viral pathogens. Here, we demonstrate that GAS7 expression within macrophages restricts the replication of viral pathogens belonging to all major viral groups. We show that the antiviral activity of GAS7 exists even under conditions where the classical antiviral response mediated by type I interferon is neutralized. In particular, we show that in human monocyte-derived macrophages, silencing of GAS7 boosts the replication of multiple viral pathogens representing most relevant viral groups. These include the retroviruses HIV-1 (human immunodeficiency virus type 1) and HIV-2 (human immunodeficiency virus type 2), the RNA viruses Zika virus (positive-sense single-stranded RNA), Sindbis virus (single-stranded positive-sense RNA), Sendai virus (negative-sense single-stranded RNA), VSV virus (negative-sense single-stranded RNA), and measles virus (negative-sense single-stranded RNA), and the DNA virus HSV-1 virus (double-stranded DNA). Importantly, the antiviral activity of GAS7 is present even under conditions where type I interferon is neutralized by the addition of the B18R protein (which efficiently blocks the type I receptor). Furthermore, the inventors demonstrate that by forcing macrophages to overexpress GAS7, they are further protected from HIV-1 infection compared to cells expressing this factor at normal levels. Therefore, the present invention relates to the modulation of GAS7 expression and / or activity for modulating viral replication in macrophage populations.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3

Recombinant polypeptide and application thereof

The invention belongs to the field of immunology, and relates to a recombinant polypeptide and application thereof.According to the recombinant polypeptide, an E2 structural domain of a Sindbis virus is modified, so that the cell recognition (binding) function of the E2 structural domain is deleted, and the modified virus serves as protein for promoting membrane fusion of CNV and target cells; meanwhile, a receptor ligand, an antibody or a functional fragment thereof, a single-domain antibody or DARPin and the like are used as molecules for providing targeting for the CNV, the molecules such as the antibody and the like are combined with surface antigens of target cells such as cancer cells, and the fusion of the CNV and a plasma membrane of the target cells is promoted by the protein for promoting membrane fusion, so that the drug molecules carried in the CNV exert an excellent cancer treatment effect. Compared with the CNV which does not express the protein for promoting membrane fusion, the modified CNV provided by the invention greatly improves the membrane fusion efficiency, and further improves the treatment effect of drugs.
Owner:REGENECORE BIOTECH CO LTD

Trans-replicating and self-replicating RNAS comprising a modified 5' UTR region

PCT designated stageWO2025171152A1Virus peptidesViruses/bacteriophagesSindbis virusVirus
This disclosure provides trans replicating RNAs (trRNA) and self- amplifying RNAs (saRNAs) with 5' Sindbis virus (SINV) untranslated region (UTR) extensions that modify trRNA / saRNA amplification and payload expression. This disclosure also describes a high throughput method for determining trRNA / saRNA amplification changes induced by 5' UTR extensions.
Owner:AMPLITUDE THERAPEUTICS INC

Application of insect protein Sniffer and homologous protein of insect protein Sniffer in insect-borne virus infection resistance

The invention discloses an insect protein Sniffer (Sni) and application of homologous protein of the insect protein Sniffer (Sni) in resistance to arthrovirus infection, and belongs to the technical field of biology. The insect protein Sni is drosophila melanogaster Sni protein, and homologous protein of the insect protein Sni comprises aedes albopictus, aedes aegypti and human homologous protein. The invention finds that the Sni protein plays a role in inhibiting Sindbis virus in drosophila melanogaster, and the human homologous protein CBR3 of the Sni protein also can play an antiviral role in U2OS cells; in addition, the Sni protein homologous protein also plays a key role in mosquitoes infected with Sindbis virus, and can resist virus infection of aedes aegypti and aedes albopictus. Based on the effects of the drosophila melanogaster Sni protein and the homologous protein thereof, overexpression of the Sni protein or the homologous protein thereof can weaken the capacity of vector insects for carrying the Sindbis virus, so that infection and propagation of the Sindbis virus in nature are controlled; the Sni protein or the homologous protein thereof can also be used for developing anti-Sindbis virus drugs.
Owner:WUHAN UNIV

Neurotoxicity-free VSV vector recombinant oncolytic virus carrying Sindbis virus G protein

The invention discloses a neurotoxicity-free VSV vector recombinant oncolytic virus carrying Sindbis virus G protein, which is characterized in that a G protein coding gene of wild type VSV is replaced by a G protein coding gene of Sindbis virus through a reverse genetic manipulation technology, so that the recombinant oncolytic virus VSV-SING capable of being autonomously replicated is saved and obtained. The invention has the advantages of no neurotoxicity and efficient oncolytic activity.
Owner:ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD

Dendritic cell-targeted viroid DVLP, and preparation method therefor and use thereof

A dendritic cell-targeted viroid DVLP, and a preparation method therefor and use thereof. The viroid DVLP is composed of VLP coated with an optimized Sindbis virus glycoprotein having a sequence as shown in SEQ ID NO.1. The preparation method therefor comprises: optimizing amino acids of an envelope protein of a wild-type Sindbis virus to obtain an SV-G gene sequence; constructing an SV-G gene expression vector pCMV-SV-G; co-transfecting HEK293T cells with the pCMV-SV-G, pRSV-REV, an antigen expression vector, pMDlg / PRE-D64V and pMS2S-PH-gagpol-D64V plasmid, and performing transfection and purification. The viroid DVLP has a very high DC cell targeting and protein stability, and after injection, the mRNA carried thereby is mainly concentrated at an injection site and a lymph node, with a low risk of diffusing to a non-target organ, such as spleen, liver, and kidney. Moreover, the viroid DVLP can generate a high-titer neutralizing antibody to fight virus infection and protect a host, and provide a platform for the development of tumor vaccines.
Owner:SHANGHAI BDGENE TECH CO LTD

Sandbis virus-like particle trVLP-ASV with transcriptional and replication capabilities and application of Sandbis virus-like particle trVLP-ASV

The invention relates to the technical field of bioengineering, in particular to a virus-like particle trVLP-ASV which has transcription and replication capabilities, is based on a Sindbis virus and displays a receptor binding domain of SARS-CoV-2 Spike protein and application. The genome of the trVLP-ASV provided by the invention does not contain an RNA replicase nsP4 gene, but inversely expresses the nsP4 gene in a BHK-21 cell, so that the possibility of biological hazards is greatly reduced; the trVLP-ASV which mainly depends on ACE2 as a receptor is formed by carrying out engineering transformation on a structural protein E2 of a Sindbis virus. The method can be used as a platform for analyzing the virus immune escape process and identifying adaptive mutation promoting virus cross-species transmission, has the advantages of safety, rapidness, flexibility and high efficiency, and has important significance on monitoring of continuous evolution of viruses and development of clinical coping strategies.
Owner:PEKING UNIV +1